| Sep 27 |
Bristol-Myers Squibb: Unlocking Value With KarXT FDA Approval And Oncology Pipeline Progress
|
| Sep 27 |
Stock Market Today: Stocks higher on muted PCE inflation data
|
| Sep 27 |
These Stocks Are Moving the Most Today
|
| Sep 27 |
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults
|
| Sep 27 |
Bristol-Myers wins FDA nod for first-of-its-kind antipsychotic
|
| Sep 27 |
Bristol-Myers Squibb's Novel Schizophrenia Drug Wins FDA Approval; BMY Stock Signals Breakout
|
| Sep 26 |
First Novel Schizophrenia Treatment in Decades Gains FDA Approval
|
| Sep 26 |
Bristol Myers schizophrenia drug, the first of its kind, approved by FDA
|
| Sep 26 |
Merck, Bristol-Myers fail to convince FDA AdCom on wider Opdivo, Keytruda use
|
| Sep 26 |
BMS and 2seventy bio to discontinue enrolment in multiple myeloma trial
|
